IC
EXAS

Innealta Capital’s Exact Sciences EXAS Stock Holding History

Innealta Capital’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-144
Closed -$6.08K – 666
2024
Q2 		$6.08K Buy
+144
New +$7.92K ﹤0.01% 898

Other funds holding EXAS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Innealta Capital's EXAS Position: Q3 2024 in Review

Innealta Capital sold out of Exact Sciences (EXAS) in Q3 2024, closing a stake of 144 shares — an estimated $6.08K sold.

Innealta Capital first reported a position in EXAS in Q2 2024 and held it in 1 quarter. The position peaked at $6.08K in Q2 2024. 599 funds tracked by Wall St. Rank hold EXAS as of Q3 2024.

  • Innealta Capital reported no remaining Exact Sciences position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 144 Exact Sciences shares in Q3 2024, an estimated $6.08K.
  • Innealta Capital first reported a position in Exact Sciences in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Exact Sciences position peaked at $6.08K in Q2 2024.
  • 599 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.